Break it Down: Orthocell raises $30m to fast-track US rollout of Remplir nerve-repair tech
Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.
In this episode, host Tylah Tully unpacks the latest news from Orthocell (ASX:OCC), who has raised $30 million to accelerate global commercialisation of its flagship nerve-repair product Remplir.
The fresh capital will be used to expand manufacturing capacity at Orthocell’s WA facility, speed up Remplir’s U.S. launch and advance clinical studies exploring its use in prostate cancer surgery.
The company will also commercialise further regenerative medicine applications in tendon, ligament, and bone repair.
Watch the video for more.
While Orthocell is a Stockhead advertiser, it did not sponsor this content.
Related Stories
UNLOCK INSIGHTS
Discover the untold stories of emerging ASX stocks.
Daily news and expert analysis, it's free to subscribe.
By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.
